CN110831584B - 具有新颖的组合物、组合的靶向药物拯救及其方法 - Google Patents

具有新颖的组合物、组合的靶向药物拯救及其方法 Download PDF

Info

Publication number
CN110831584B
CN110831584B CN201880037396.3A CN201880037396A CN110831584B CN 110831584 B CN110831584 B CN 110831584B CN 201880037396 A CN201880037396 A CN 201880037396A CN 110831584 B CN110831584 B CN 110831584B
Authority
CN
China
Prior art keywords
compound
dextromethorphan
formula
phenoxy
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880037396.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831584A (zh
Inventor
斯瑞尼瓦萨饶·韦帕切杜
汉斯·J·莫比乌斯
安东·贝斯帕洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exeva Co ltd
Original Assignee
Exeva Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by Exeva Co ltd filed Critical Exeva Co ltd
Publication of CN110831584A publication Critical patent/CN110831584A/zh
Application granted granted Critical
Publication of CN110831584B publication Critical patent/CN110831584B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880037396.3A 2017-05-04 2018-05-03 具有新颖的组合物、组合的靶向药物拯救及其方法 Active CN110831584B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
US62/501,696 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
USPCT/US2017/048748 2017-08-25
US201862634162P 2018-02-22 2018-02-22
US62/634,162 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US62/635,554 2018-02-27
US62/636,099 2018-02-27
US201862636171P 2018-02-28 2018-02-28
US62/636,171 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (2)

Publication Number Publication Date
CN110831584A CN110831584A (zh) 2020-02-21
CN110831584B true CN110831584B (zh) 2023-03-10

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880037396.3A Active CN110831584B (zh) 2017-05-04 2018-05-03 具有新颖的组合物、组合的靶向药物拯救及其方法

Country Status (13)

Country Link
EP (1) EP3618819A4 (https=)
JP (2) JP7514078B2 (https=)
KR (2) KR20200062078A (https=)
CN (1) CN110831584B (https=)
AU (2) AU2018261654A1 (https=)
BR (1) BR112019022902A2 (https=)
CA (2) CA3062452C (https=)
IL (1) IL270326B2 (https=)
MA (1) MA49464A (https=)
RU (1) RU2760558C9 (https=)
TW (1) TWI787260B (https=)
WO (1) WO2018204713A1 (https=)
ZA (1) ZA201908006B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
AU2020241611A1 (en) * 2019-03-18 2021-11-04 Avanir Pharmaceuticals, Inc. Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN119432479B (zh) * 2023-08-04 2025-10-03 中国石油天然气股份有限公司 柴油机润滑油组合物及其制备方法
CN120987847B (zh) * 2024-11-29 2026-02-17 江苏恩华药业股份有限公司 一种氢溴酸右美沙芬的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP1986639A4 (en) 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
WO2014138669A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
EP2972329A2 (en) 2013-03-15 2016-01-20 Kinemed, Inc. Biomarkers
MY198587A (en) * 2014-09-14 2023-09-06 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans;Jee Sun Min et al.;《Drug Design, Development and Therapy》;20160901;第10卷(第1期);第2965页表3 *
Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes;DOO-YEOUN CHO et al.;《Drug Metabolisim and Disposition》;20140131;第42卷;第33页摘要及34页图1 *
盐酸沙格雷酯对大鼠体内细胞色素P4502D1/2 的影响;许美娟等;《中国药理学通报》;20141231;第30卷(第12期);第1739页摘要 *

Also Published As

Publication number Publication date
TWI787260B (zh) 2022-12-21
JP7514078B2 (ja) 2024-07-10
KR102444803B1 (ko) 2022-09-19
IL270326A (https=) 2018-05-03
JP2020518617A (ja) 2020-06-25
RU2760558C2 (ru) 2021-11-29
CA3062452C (en) 2023-10-24
TW201842902A (zh) 2018-12-16
KR20200062078A (ko) 2020-06-03
EP3618819A1 (en) 2020-03-11
RU2760558C9 (ru) 2022-02-22
AU2018261654A1 (en) 2019-11-14
MA49464A (fr) 2020-04-29
KR20210130827A (ko) 2021-11-01
JP2023143940A (ja) 2023-10-06
CN110831584A (zh) 2020-02-21
EP3618819A4 (en) 2021-01-20
RU2019137004A (ru) 2021-06-04
CA3138116A1 (en) 2018-11-08
IL270326B (en) 2022-10-01
AU2021215274B2 (en) 2022-11-03
BR112019022902A2 (pt) 2020-05-19
CA3062452A1 (en) 2018-11-08
RU2019137004A3 (https=) 2021-06-04
IL270326B2 (en) 2023-02-01
WO2018204713A1 (en) 2018-11-08
ZA201908006B (en) 2021-04-28
AU2021215274A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CN110831584B (zh) 具有新颖的组合物、组合的靶向药物拯救及其方法
JP7096813B2 (ja) 組成物及びその方法
JP2026010068A (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
EP4346788A2 (en) Enantiomeric entactogen compositions and methods of their use
JP5226053B2 (ja) ベンジルイソキノリン誘導体またはビスベンジルイソキノリン誘導体を含有する向精神薬、鎮痛薬および／または抗炎症薬、ならびに健康食品
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2020512986A (ja) 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
JP2024508545A (ja) セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
US20220296586A1 (en) Novel compositions, combinations, and methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant